TolerogenixX Phase Ib safety data cited to back TOL-2 kidney tolerance program
A 14-patient Phase Ib readout completed nine years ago now anchors TolerogenixX's push for EU approval, with the real test, a 63-pair Phase IIb trial, due in H1 2027.
Executive Summary
- TolerogenixX disclosed that its completed early-phase kidney transplant trial showed favorable safety and tolerability after a single cell therapy administration, without releasing numeric endpoint data.
- The company paired that disclosure with new European Orphan Drug and PRIME designations, which mark regulatory support for an unmet need rather than a signal about clinical benefit.
- The real test of whether the cell therapy can reduce reliance on lifelong immunosuppression sits in a larger, randomized, controlled trial with results expected within the next year.
- Kidney transplant rejection and immunosuppression research includes several late-stage programs testing different mechanisms, and this therapy's approach has no active same-mechanism comparator among them.
The disclosure
TolerogenixX, a Heidelberg-based cell therapy company, said the European Commission granted MIC-Lx Orphan Drug Designation for living-donor kidney transplantation, following an earlier EMA PRIME designation. In the same release, the company pointed to its completed Phase Ib trial, TOL-1, run at Heidelberg University and registered as NCT02560220, as evidence supporting the therapy's approach. The trial enrolled 14 patients, reached its primary completion in April 2017, and closed with a Completed status; the registry record has not been updated since May 2020. TolerogenixX+1TolerogenixX Has Received EMA Orphan Drug Designation for MIC-Lx, Strengthening its Regulatory ...Jul 13, 2026MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant RecipientsNCT02560220
What TOL-1 measured
TOL-1 was designed as a single-arm, open-label Phase 1 study, with its primary outcome measure defined as the frequency of adverse events within 30 days after transplantation following intravenous administration of the modified immune cells. TolerogenixX's release states the trial showed sustained safety and tolerability after a single administration and preservation of normal immune responses, but the release did not include a numeric adverse-event rate, a p-value, or 30-day endpoint data. No results have been posted to the trial's ClinicalTrials.gov record. A 14-patient, uncontrolled safety cohort completed nearly a decade ago is capable of establishing that a single dose was tolerated; it cannot establish that the therapy reduces rejection risk or immunosuppression burden, which requires a controlled comparison. NCT02560220+1MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant RecipientsNCT02560220TolerogenixX Has Received EMA Orphan Drug Designation for MIC-Lx, Strengthening its Regulatory ...Jul 13, 2026
The controlled test ahead
That controlled comparison is the ongoing Phase IIb trial, TOL-2, which the company describes as randomized and controlled and which has finished treating all 63 donor-recipient pairs and entered its follow-up phase, with topline results expected in the first half of 2027. Prof. Dr. Matthias Schaier, TolerogenixX's chief executive, said the designations recognize "our first-in-class approach and support the ongoing development of MIC-Lx". Prof. Dr. Christian Morath, the company's chief scientific officer, said the therapy "is designed to induce donor-specific immune tolerance before transplantation, with the goal of protecting the graft while preserving broader immune competence". TolerogenixXTolerogenixX Has Received EMA Orphan Drug Designation for MIC-Lx, Strengthening its Regulatory ...Jul 13, 2026
Where it sits competitively
Kidney transplant rejection and rejection-prophylaxis research includes several Phase 3 programs testing distinct mechanisms, including Bristol-Myers Squibb's costimulation blocker belatacept in allograft rejection prophylaxis and Biogen's CD38-targeting felzartamab in antibody-mediated rejection. None of those programs shares MIC-Lx's cell-based tolerance-induction approach, so the therapy has no active same-mechanism comparator in the trials tracked for this indication; the closest points of reference are contextual neighbors that share only the transplant-rejection setting, not the biology. Because no validated cell-based tolerance-induction therapy exists in this setting, the informative test for MIC-Lx is whether the controlled Phase IIb trial shows a durable reduction in immunosuppression need or improved graft outcomes relative to standard care, not incremental safety data alone.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.